who should not take glp-1 receptor agonists glp 1 drugs The and Obesity: How Diabetes Drugs GLP-1 Agonists For Obesity In

Diabetes Obes Metab 23:529 Holst JJ (2019) The incretin system in healthy humans: The role of GIP and GLP-1

[DOI] [PubMed] [Google Scholar] 23.Lpez de Maturana R, Donnelly D

GLP-1 RA-Related Facial Aging The rapid and significant weight loss induced by GLP-1 RAs often leads to a noticeable reduction in facial fat pad volume, along with a decline in skin collagen, elastin, and essential nutrients

As many of their effects influence weight loss and management, the variety of formulations provide tailored treatment options for many individuals

Researchers reported 75 ADRD cases among GLP-1 users over a mean follow-up of 2.22 years, compared with 639 ADRD cases among other GLD users over mean follow-up of 3.74 years